Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSanchez Alberti, Andrés
Bivona, Augusto E
Padilla, Angel M
Cazorla, Silvia I
Tarleton, Rick L
Guzmán, Carlos A
Malchiodi, Emilio L
MetadataShow full item record
AbstractThe parasite Trypanosoma cruzi is the causative agent of Chagas disease, a potentially life-threatening infection that represents a major health problem in Latin America. Several characteristics of this protozoan contribute to the lack of an effective vaccine, among them: its silent invasion mechanism, T. cruzi antigen redundancy and immunodominance without protection. Taking into account these issues, we engineered Traspain, a chimeric antigen tailored to present a multivalent display of domains from key parasitic molecules, combined with stimulation of the STING pathway by c-di-AMP as a novel prophylactic strategy. This formulation proved to be effective for the priming of functional humoral responses and pathogen-specific CD8+ and CD4+ T cells, compatible with a Th1/Th17 bias. Interestingly, vaccine effectiveness assessed across the course of infection, showed a reduction in parasite load and chronic inflammation in different proof of concept assays. In conclusion, this approach represents a promising tool against parasitic chronic infections.
CitationEngineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection. 2017, 2:9 NPJ Vaccines
AffiliationHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.
- Authors: Matos MN, Cazorla SI, Schulze K, Ebensen T, Guzmán CA, Malchiodi EL
- Issue date: 2017 Feb
- Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.
- Authors: Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL
- Issue date: 2014 Aug
- A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.
- Authors: Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA
- Issue date: 2014 Jun 12
- Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
- Authors: Gupta S, Garg NJ
- Issue date: 2010 Aug 10
- Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
- Authors: Bhatia V, Garg NJ
- Issue date: 2008 Aug